Exelixis (EXEL) Set to Announce Earnings on Wednesday

Exelixis (NASDAQ:EXEL) will post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Exelixis to post earnings of $0.19 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.02. The firm had revenue of $240.28 million for the quarter, compared to analysts’ expectations of $226.97 million. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. Exelixis’s quarterly revenue was up 29.1% on a year-over-year basis. During the same quarter last year, the company earned $0.31 EPS. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Exelixis stock opened at $16.76 on Wednesday. The stock has a market cap of $5.09 billion, a price-to-earnings ratio of 11.72 and a beta of 1.81. The company has a current ratio of 8.64, a quick ratio of 8.53 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $18.13 and its two-hundred day moving average price is $20.13. Exelixis has a 52 week low of $13.42 and a 52 week high of $25.31.

In other news, Director George Poste sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $20.60, for a total transaction of $412,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Morrissey sold 35,040 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $20.25, for a total transaction of $709,560.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 350,974 shares of company stock valued at $7,005,921. Insiders own 4.50% of the company’s stock.

Several equities analysts have commented on the stock. BidaskClub cut shares of Exelixis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. Zacks Investment Research cut shares of Exelixis from a “hold” rating to a “sell” rating and set a $19.00 target price on the stock. in a research note on Thursday, October 3rd. ValuEngine raised shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 10th. Stifel Nicolaus raised their target price on shares of Exelixis from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, August 1st. Finally, BMO Capital Markets lowered their target price on shares of Exelixis from $23.00 to $19.00 and set a “market perform” rating on the stock in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $27.13.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: Real Estate Investment Trust (REIT) ETF

Earnings History for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.